Flucloxacillin-associated hepatic injury
- PMID: 7997079
- DOI: 10.1111/j.1600-0676.1994.tb00079.x
Flucloxacillin-associated hepatic injury
Abstract
Eleven cases of hepatic injury attributed to the intake of flucloxacillin were reported to the Netherlands Center for Monitoring of Adverse Reactions to Drugs between 1982 and 1992. They concerned four men and seven women, with a mean age of 57 years, treated for 2-28 days with an oral dose varying from 1500-4000 mg per day. Symptoms mostly appeared 10 to 30 days after starting treatment with flucloxacillin. Biochemically, the pattern was compatible with cholestatic hepatitis in seven cases, with a mixed cholestatic-hepatocellular type of injury in one case, a hepatocellular pattern in two cases, and mild liver enzyme elevations in one patient. Two patients died, one due to fatal bleeding from the liver after biopsy, and the second patient to a combination of hepatic and cardiac failure. The other patients recovered, on average 72 days after peaking of serum aminotransferase values. Histology in seven cases showed cholestatic hepatitis in five, with cholangitis or cholangiolitis in four of these patients. In the other two patients, there was centrilobular cholestasis with extensive bridging fibrosis and portal-central bridging necrosis, respectively.
Similar articles
-
Flucloxacillin induced delayed cholestatic hepatitis.Aust N Z J Med. 1990 Jun;20(3):251-3. doi: 10.1111/j.1445-5994.1990.tb01032.x. Aust N Z J Med. 1990. PMID: 2372276
-
Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases.J Hepatol. 1986;3(3):399-406. doi: 10.1016/s0168-8278(86)80495-0. J Hepatol. 1986. PMID: 3559147
-
Flucloxacillin and cholestatic hepatitis.Med J Aust. 1994 Apr 18;160(8):525. Med J Aust. 1994. PMID: 8170433 No abstract available.
-
Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic?Eur J Clin Pharmacol. 1995;49(1-2):81-5. doi: 10.1007/BF00192363. Eur J Clin Pharmacol. 1995. PMID: 8751026 Review.
-
Flucloxacillin-induced liver injury.Toxicology. 2008 Dec 30;254(3):158-63. doi: 10.1016/j.tox.2008.08.009. Epub 2008 Aug 29. Toxicology. 2008. PMID: 18793693 Review.
Cited by
-
[Elevated liver enzymes in rheumatoid arthritis : differential diagnostic considerations based on a case report].Z Rheumatol. 2008 Sep;67(5):440-4. doi: 10.1007/s00393-008-0288-3. Z Rheumatol. 2008. PMID: 18418614 German.
-
Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A-catalysed hydroxylation by sulfaphenazole.Br J Pharmacol. 2019 Feb;176(3):466-477. doi: 10.1111/bph.14548. Epub 2018 Dec 26. Br J Pharmacol. 2019. PMID: 30447161 Free PMC article.
-
Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man.Arch Toxicol. 2016 Dec;90(12):2979-3003. doi: 10.1007/s00204-016-1845-1. Epub 2016 Sep 22. Arch Toxicol. 2016. PMID: 27659300 Free PMC article. Review.
-
Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.Br J Clin Pharmacol. 2005 Jul;60(1):76-82. doi: 10.1111/j.1365-2125.2005.02370.x. Br J Clin Pharmacol. 2005. PMID: 15963097 Free PMC article.
-
Genetic Variations and Antibiotic-Related Adverse Events.Pharmaceuticals (Basel). 2024 Mar 2;17(3):331. doi: 10.3390/ph17030331. Pharmaceuticals (Basel). 2024. PMID: 38543117 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical